Product Description

Indications: Coralcin-D tablet is indicated for the treatment and prevention of osteoporosis, osteomalacia, tetany, hypoparathyroidism, and disorders of osteogenesis. It is also used as a calcium supplement in cases of inadequate dietary calcium intake during childhood, rickets, pregnancy, lactation, and in elderly patients. Additional uses include pancreatitis and as a phosphate binder in chronic renal failure.

Composition: Each Coralcin-D tablet contains Calcium Carbonate USP 1250 mg from coral source, equivalent to 500 mg elemental Calcium, along with Vitamin D USP 200 IU. Each DX tablet contains Calcium Carbonate USP 1500 mg equivalent to 600 mg elemental Calcium and Vitamin D USP 400 IU. Each effervescent tablet contains Calcium Carbonate USP 1500 mg equivalent to 600 mg elemental Calcium and Vitamin D3 400 IU as Cholecalciferol USP.

Pharmacology: Calcium plays a vital role in maintaining numerous physiological functions and bone health. Clinical evidence supports its use in preventing and treating osteoporosis and fracture-related complications. Vitamin D enhances calcium absorption from the gastrointestinal tract and promotes bone mineralization and formation. The combination of calcium and vitamin D provides synergistic benefits in maintaining healthy bones and preventing bone-related disorders. Coral-derived Calcium Carbonate has a mineral structure similar to human bone and may offer improved absorption compared to conventional sources. Vitamin D3 helps maintain calcium balance and supports effective calcium utilization in the body.

Dosage & Administration: The usual dose is one tablet once or twice daily with plenty of water or as directed by the physician. Taking the tablet after meals improves absorption. For effervescent tablets, dissolve one tablet in a glass of water, stir well, and drink immediately after preparation.

Interaction: Thiazide diuretics may reduce urinary calcium excretion and increase the risk of hypercalcemia, requiring regular monitoring of serum calcium levels. Systemic corticosteroids may decrease calcium absorption, possibly necessitating higher calcium doses. Cholestyramine and paraffin oil may reduce vitamin D absorption. Calcium carbonate may interfere with the absorption of tetracyclines; therefore, tetracyclines should be taken at least two hours before or four to six hours after calcium supplementation. Hypercalcemia may increase the toxicity of cardiac glycosides, requiring ECG and calcium monitoring. Bisphosphonates and sodium fluoride should be administered at least three hours before Coralcin-D. Foods rich in oxalic acid or phytic acid, such as spinach, rhubarb, and whole cereals, may impair calcium absorption.

Contraindications: Contraindicated in patients with hypercalcemia, hyperparathyroidism, hypercalciuria, nephrolithiasis, severe renal insufficiency, hypersensitivity to any component of the formulation, and in patients receiving digoxin therapy without proper calcium monitoring.

Side Effects: Calcium carbonate may occasionally irritate the gastrointestinal tract and cause constipation. Other possible side effects include nausea, vomiting, decreased appetite, dry mouth, drowsiness, irregular heartbeat, allergic reactions, and hypercalcemia, particularly in patients with renal impairment. Skin rash has occasionally been reported with vitamin D supplementation.

Pregnancy & Lactation: During pregnancy, daily intake should not exceed 1500 mg calcium and 600 IU vitamin D unless prescribed. Excessive intake may cause fetal complications related to hypercalcemia. Coralcin-D may be used during pregnancy and breastfeeding in cases of calcium and vitamin D deficiency. Both calcium and vitamin D pass into breast milk and should be considered when giving additional vitamin D to infants.

Precautions & Warnings: Long-term therapy requires periodic monitoring of serum calcium and renal function, especially in elderly patients, those receiving cardiac glycosides or diuretics, and individuals prone to kidney stone formation. Treatment should be reduced or discontinued if hypercalcemia or renal impairment develops. Use vitamin D cautiously in patients with renal dysfunction, sarcoidosis, or immobilized osteoporosis due to increased risk of hypercalcemia and soft tissue calcification. Additional calcium or vitamin D supplementation should only be taken under close medical supervision.

Overdose Effects: Overdose may lead to hypervitaminosis D and hypercalcemia. Symptoms may include nausea, vomiting, constipation, abdominal pain, excessive thirst, polyuria, muscle weakness, fatigue, confusion, nephrolithiasis, nephrocalcinosis, cardiac arrhythmias, and in severe cases coma or death. Treatment includes discontinuation of calcium and vitamin D, rehydration, and supportive therapy with loop diuretics, bisphosphonates, calcitonin, or corticosteroids depending on severity. Monitoring of renal function, serum electrolytes, ECG, and fluid balance is essential.

Therapeutic Class: Specific mineral and vitamin combined preparations.

Storage Conditions: Store below 30°C in a cool, dry place protected from light and moisture. Keep out of reach of children.